Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ZURA

Zura Bio

ZURA Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓ 22 filings & releases ↓ Cash $188M (Sep 30, 2026) ↓ 2 verdicts ↓ 4 timing quotes ↓
DermatologyImmunology Protein

Market cap $394M 96.3M shares (10-Q, Oct 27, 2026) × $4.09 close Nov 6, 2026

Most recent annual filing: 2026-03-19

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Third indication undisclosed Ph2 startby year-end 2026Third indication undisclosed Ph2 start, by year-end 2026, routine
  2. Tibulizumab TibuSHIELD topline4Q 2026Tibulizumab TibuSHIELD topline, 4Q 2026, thesis-defining
  3. Tibulizumab TibuSURE topline1H 2027Tibulizumab TibuSURE topline, 1H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Capital (as filed)

Cash
$188M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$19K quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$205M cash, runway through at least the end of 2028 per the update of Aug 11, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Zura Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-30 Watch Zura Bio Limited (ZURA) - Scientific Deep Dive for Tibulizumab and Pipeline Products Legitimate science and de-risked financing, but the entire incremental thesis rides on the unproven BAFF arm, with governance/SPAC overhang, no specialist biotech smart money, and a stock already tripled off its lows — better to watch into Q4 2026 HS data than own ahead of it.
  2. 2026-08-12 Watch UPDATE: Zura Bio (ZURA) - The Third Shot on Goal Gets a Name Naming PMR as the third indication — where both IL-17 and B-cell arms have randomized clinical support — narrows the bear case modestly, but the BAFF contribution in HS remains unproven and Q4 2026 remains a binary with the stock more than tripled off its lows.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (22)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)